⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 3, 2024

Supplemental Table 5 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis

Jack Pengfei Tang Pénélope Lafeuille Alexandru Socolov Sheila S. Diamond Jacob Aptekar Theodore B. Moore Esther H. Nie Mark R. Hanudel Theodore S. Nowicki

View at Publisher

Ask AI

Bookmark

Share

Abstract

Correlation between ICANS, CRS, and various electrolyte derangements with categories of neurological adverse events reported in CAR T-cell recipients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tang et al. (2024) studied this question.

synapsesocial.com/papers/68e55ee7e2b3180350efbe20 https://doi.org/10.1158/2767-9764.27160794

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Table 1 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis2024
2Supplemental Table 3 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis2024
3Figure 3 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis2024
4Supplemental Table 2 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis2024
5Figure S2 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis2024

More related papers

Supplemental Table 4 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis2024
Supplemental Table 6 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis2024
Figure S1 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis2024